Short Interest in scPharmaceuticals Inc. (NASDAQ:SCPH) Rises By 19.9%

scPharmaceuticals Inc. (NASDAQ:SCPH) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 5,780,000 shares, a growth of 19.9% from the May 31st total of 4,820,000 shares. Based on an average trading volume of 237,500 shares, the short-interest ratio is presently 24.3 days. Approximately 26.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SCPH. Rubric Capital Management LP boosted its position in shares of scPharmaceuticals by 29.0% during the 4th quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company’s stock valued at $21,945,000 after acquiring an additional 786,713 shares during the last quarter. AIGH Capital Management LLC increased its position in scPharmaceuticals by 40.8% during the fourth quarter. AIGH Capital Management LLC now owns 3,106,795 shares of the company’s stock valued at $19,480,000 after acquiring an additional 899,786 shares during the last quarter. King Luther Capital Management Corp increased its position in scPharmaceuticals by 48.8% during the fourth quarter. King Luther Capital Management Corp now owns 1,393,525 shares of the company’s stock valued at $8,737,000 after acquiring an additional 457,150 shares during the last quarter. Worth Venture Partners LLC raised its stake in shares of scPharmaceuticals by 42.9% in the fourth quarter. Worth Venture Partners LLC now owns 771,344 shares of the company’s stock valued at $4,836,000 after acquiring an additional 231,679 shares during the period. Finally, Rice Hall James & Associates LLC boosted its stake in shares of scPharmaceuticals by 247.0% during the 1st quarter. Rice Hall James & Associates LLC now owns 281,105 shares of the company’s stock worth $1,411,000 after purchasing an additional 200,101 shares during the period. 89.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research report on Wednesday, May 15th.

scPharmaceuticals Stock Down 0.7 %

SCPH stock opened at $4.32 on Tuesday. The stock has a market cap of $155.74 million, a P/E ratio of -2.92 and a beta of 0.12. The company has a quick ratio of 5.44, a current ratio of 6.21 and a debt-to-equity ratio of 1.60. The business’s 50-day moving average price is $4.22 and its 200-day moving average price is $5.08. scPharmaceuticals has a twelve month low of $3.24 and a twelve month high of $10.09.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. scPharmaceuticals had a negative return on equity of 132.39% and a negative net margin of 327.29%. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.50 million. During the same period in the previous year, the business earned ($0.30) earnings per share. On average, equities research analysts forecast that scPharmaceuticals will post -1.46 EPS for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.